Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology

J Alzheimers Dis. 2009;18(3):509-13. doi: 10.3233/JAD-2009-1183.

Abstract

Previous studies showed that memantine inhibits tau hyperphosphorylation in vitro. In this study, phosphorylated tau (P-tau) and total tau (T-tau) were measured before and after 6 month treatment with memantine in 12 subjects ranging from normal cognition with subjective memory complaints, through mild cognitive impairment to mild Alzheimer's disease. Thirteen non-treated individuals served as controls. Treatment was associated with a reduction of P-tau in subjects with normal cognition. No treatment effects were seen among impaired individuals, suggesting that longer treatment time may be necessary to achieve biomarker effect in this group.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease* / cerebrospinal fluid
  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / pathology
  • Antiparkinson Agents / pharmacology*
  • Antiparkinson Agents / therapeutic use*
  • Biomarkers / cerebrospinal fluid
  • Brain / pathology*
  • Cognition Disorders / diagnosis
  • Cognition Disorders / drug therapy
  • Cognition Disorders / pathology
  • Female
  • Humans
  • Male
  • Memantine / pharmacology*
  • Memantine / therapeutic use*
  • Neurofibrillary Tangles / pathology*
  • Neuropsychological Tests
  • Phosphorylation / drug effects
  • Severity of Illness Index
  • Spinal Puncture
  • tau Proteins / metabolism

Substances

  • Antiparkinson Agents
  • Biomarkers
  • tau Proteins
  • Memantine